AsthmaCON-PONCT07134686
Implementation of a Joint Pulmonologist and ENT Consultation in the Care Pathway of Patients Suffering From Asthma and Chronic Rhinosinusitis With Nasal Polyposis: Effectiveness Compared With Consultations by Specialty (CON-PO Study).
A study testing Joint consultation, Mucus sampling and Nasal brushing in people with Asthma and Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), run by Assistance Publique Hopitaux De Marseille at 1 site in France.
Trial summary
Asthma affects the lower respiratory tract (bronchi), whereas chronic rhinosinusitis with nasal polyposis (CRSwNP) involves the upper airways. Despite this anatomical distinction, the upper and lower airways form a continuous respiratory tract and share common pathophysiological mechanisms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Asthma, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- What is being tested?
- Joint consultation, Mucus sampling and Nasal brushing
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 195 participants
- Where
- 1 siteFrance
- Study dates
- 28 Jul 2026to Nov 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female, 18 years of age or older;
- With a diagnosis of asthma;
- With a diagnosis of chronic rhinosinusitis with nasal polyposis;
- Whose asthma and/or chronic rhinosinusitis is/are not controlled according to SNOT-22 and ACQ-6 scores;
- Having used systemic corticosteroids in the previous year to treat symptoms related to one of these conditions at least;
Who cannot join
- Patient in a period of exclusion from another research protocol at the time of consent signature;
- Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (adult patients under guardianship or curatorship, patients deprived of their liberty, pregnant or breast-feeding women);
- Patients who do not read and/or understand French
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
AP-HM
Marseille
Laurie Pahus, +334 91 96 45 33, promotion.interne@ap-m.fr
About this study
Asthma affects the lower respiratory tract (bronchi), whereas chronic rhinosinusitis with nasal polyposis (CRSwNP) involves the upper airways. Despite this anatomical distinction, the upper and lower airways form a continuous respiratory tract and share common pathophysiological mechanisms. Consequently, asthma and CRSwNP frequently coexist, and several therapeutic strategies are effective for both conditions.
Given these overlaps, we hypothesize that a multidisciplinary consultation involving both a pulmonologist and an ENT specialist could be more effective than separate consultations for patient care. We also believe that this innovative organization that would benefit the healthcare system.
Read more
To test this hypothesis, we are conducting a study whose primary objective is to assess whether joint consultations lead to a reduction in oral corticosteroid need over the year following the initial consultation, by enabling more personalized treatment strategies.
Secondary outcomes will include the frequency of asthma exacerbations, frequency of ENT-related events, respiratory symptoms, quality of life, and healthcare ressources utilization.
We will compare outcomes between two patient groups: one receiving joint consultation from both specialists, and the other managed through standard, separate consultations as per current clinical practice.
- Being tested
- Joint consultation, Mucus sampling, Nasal brushing
- Keywords
- Asthma, Care pathway, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Joint consultationOther
Joint consultation with pneumologist and ENT at baseline.
Mucus samplingProcedure or surgery
Mucus sampling at baseline and one year follow-up
Nasal brushingProcedure or surgery
Nasal brushing at baseline and one year follow-up
| Study group | Role | What they receive |
|---|---|---|
| Joint consultation | Experimental | Multi-disciplinary consultation with a pulmonologist and ENT specialist at the baseline visit Receives: Other: Joint consultation; Procedure: Mucus sampling; Procedure: Nasal brushing |
| Separate consultations | Active comparator | Separate consultations with a pulmonologist and ENT specialist at the baseline visit as standard care Receives: Procedure: Mucus sampling; Procedure: Nasal brushing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effectiveness of joint ENT and pulmonologist consultation on relative change in cumulative annual dose of oral corticosteroids from the year before Baseline to the year between Baseline and 12 months visit.
Self reported cumulative annual dose of oral corticosteroids.
Measured: From the year before Baseline to the 12 months visit.
Secondary outcomes (7)
Reduction of asthma exacerbations frequency. Relative change from the year before Baseline to the year between baseline and 12 months visit in number of asthma exacerbations.
self-reported number of asthma exacerbations
Measured: From the year before Baseline to the 12 months visit.
Reduction of ENT events frequency. Relative change from the year before baseline to the year between baseline and 12 month visit in number of ENT events.
Self reported number of ENT events
Measured: From the year before Baseline to the 12 months visit.
Improvement of asthma control. Relative change from baseline to 12 months visit in ACQ-6 score
Self-administered questionnaire
Measured: Baseline and 12 months visit.
Improvement of chronic rhinosinusitis with nasal polyposis control . Relative change from baseline to 12 months visit in SNOT-22 score
Self-administered questionnaire
Measured: Baseline and 12 months visit.
Reduction in endoscopic polyp score. Relative change from baseline to 12 months visit in the polyp endoscopic score (mean of measures of both nostrils)
Evaluated with nasal endoscopy
Measured: Baseline and 12 months visit.
Improvement of patient's quality of life. Relative change from baseline to 12 months visit in EQ-5D-5L score
Self-administered questionnaire
Measured: Baseline and 12 months visit.
Reduction of healthcare ressource use . Relative change from baseline to 12 months visit in number of consultations with a specialist, general practitionner, emergency visits and hospitalizations
Self-reported number of consultations with a specialist, general practicionner, emergency visits and hospitalizations
Measured: From Baseline to the 12 months visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2025
- Study start28 Jul 2026
- Primary completionNov 2029 (estimated)
- Study completionNov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Model Description
- Masking
- None (open label)
- Enrolment
- 195 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07134686
- Sponsor's protocol ID
- 2024-A02003-44
- Acronym
- CON-PO
- Status last verified
- Jul 2026
- First submitted
- 14 Aug 2025
- Last updated
- 3 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No